Author | Â | Gender | Age | Location | cStage | RT (Gy) | Chemotherapy | Response | Prognosis |
---|---|---|---|---|---|---|---|---|---|
Miyamoto S et al. [26] | 2009 | F | 61 | AC | IV | 30 | S-1 + CDDP | CR | Disease-free for 20 months |
Kuga Y et al. [27] | 2009 | F | 76 | AC | III | 50 | S-1 + CDDP | CR | NR |
Shiozawa M et al. [28] | 2010 | F | 48 | AC | III | 60 | S-1 + MMC | CR | Disease-free for 2 years 7 months |
 |  | F | 65 | AC | III | 55.8 | S-1 + MMC | CR | Disease-free for 2 years 4 months |
 |  | F | 71 | AC | III | 58.0 | S-1 + MMC | CR | Disease-free for 8 months |
Hata T et al. [29] | 2011 | F | 53 | AC | I | 45 | S-1 alone | CR | NR |
Baba H et al. [30] | 2011 | F | 79 | AC | III | 66 | S-1 alone | CR | Disease-free for 10 months |
Nitori N et al. [31] | 2011 | F | 58 | AC | IV | 30 | S-1 + CDDP | NR | Dead at 16 months |
Kuroda M et al. [32] | 2012 | F | 81 | AC | IV | 50.4 | S-1 + CDDP | CR | Disease-free for 1 year 3 months |
Sato H et al. [33] | 2012 | F | 83 | AC | II | 60 | S-1 alone | CR | Local recurrence at 9 months and dead at 15 months after CRT |
Murata K et al. [34] | 2012 | F | 76 | AC | II | 60 | S-1 alone | CR | Recurrence at 2 years |